For high VEGF-Axxxa , the hazard ratios ( HRs ) for progression were 1.08 ( P = .71 ) in non-bevacizumab-treated patients ( cohort A ) and 0.66 ( P = .22 ) in bevacizumab-treated patients ( cohort B ) , and the HRs for death were 1.45 ( P = .13 ) and 0.50 ( P = .049 ) , respectively .